Objectives: Autoantibody testing is helpful for predicting the risk of progression to clinical arthritis in subjects at risk. Previous longitudinal studies have mainly selected autoantibody-positive arthralgia patients, and consequently the predictive values of autoantibodies were evaluated relative to one another. This study assessed the risks for arthritis development of ACPA, RF and/or anti-carbamylated protein antibodies (anti-CarP) in arthralgia patients considered at risk for RA by rheumatologists, based on clinical characteristics (clinically suspect arthralgia, CSA). Methods: The baseline ACPA, RF and anti-CarP autoantibody status of 241 patients, consecutively included in the CSA cohort, was studied for risk of developing clinical arthritis during a median follow-up of 103 (interquartile range: 81-114) weeks. Results: Univariable associations for arthritis development were observed for ACPA, RF and anti-CarP antibodies; hazard ratios (HRs) (95% CI) were 8.5 (4.7-15.5), 5.1 (2.8-9.3) and 3.9 (1.9-7.7), respectively. In multivariable analysis, only ACPA was independently associated (HR = 5.1; 2.0-13.2). Relative to autoantibody-negative CSA patients, ACPA-negative/RF-positive patients had HRs of 2.6 (1.04-6.6), ACPA-positive/RF-negative patients 8.0 (2.4-27.4) and ACPA-positive/RF-positive patients 10.5 (5.4-20.6). Positive predictive values for development of clinical arthritis within 2 years were: 38% for ACPA-negative/RF-positive, 50% for ACPA-positive/RF-negative and 67% for ACPA-positive/RF-positive patients. Higher ACPA levels were not significantly associated with increased progression to clinical arthritis, in contrast to higher RF levels. Autoantibody levels were stable during follow-up. Conclusion: ACPA conferred the highest risk for arthritis development and had an additive value to RF. However, >30% of ACPA-positive/RF-positive CSA patients did not develop arthritis during the 2-year follow-up. Thus, CSA and information on autoantibodies is insufficient for accurately identifying imminent autoantibody-positive RA.
Objectives: Autoantibody testing is helpful for predicting the risk of progression to clinical arthritis in subjects at risk. Previous longitudinal studies have mainly selected autoantibody-positive arthralgia patients, and consequently the predictive values of autoantibodies were evaluated relative to one another. This study assessed the risks for arthritis development of ACPA, RF and/or anti-carbamylated protein antibodies (anti-CarP) in arthralgia patients considered at risk for RA by rheumatologists, based on clinical characteristics (clinically suspect arthralgia, CSA). Methods: The baseline ACPA, RF and anti-CarP autoantibody status of 241 patients, consecutively included in the CSA cohort, was studied for risk of developing clinical arthritis during a median follow-up of 103 (interquartile range: 81-114) weeks. Results: Univariable associations for arthritis development were observed for ACPA, RF and anti-CarP antibodies; hazard ratios (HRs) (95% CI) were 8.5 (4.7-15.5), 5.1 (2.8-9.3) and 3.9 (1.9-7.7), respectively. In multivariable analysis, only ACPA was independently associated (HR = 5.1; 2.0-13.2). Relative to autoantibody-negative CSA patients, ACPA-negative/RF-positive patients had HRs of 2.6 (1.04-6.6), ACPA-positive/RF-negative patients 8.0 (2.4-27.4) and ACPA-positive/RF-positive patients 10.5 (5.4-20.6). Positive predictive values for development of clinical arthritis within 2 years were: 38% for ACPA-negative/RF-positive, 50% for ACPA-positive/RF-negative and 67% for ACPA-positive/RF-positive patients. Higher ACPA levels were not significantly associated with increased progression to clinical arthritis, in contrast to higher RF levels. Autoantibody levels were stable during follow-up. Conclusion: ACPA conferred the highest risk for arthritis development and had an additive value to RF. However, >30% of ACPA-positive/RF-positive CSA patients did not develop arthritis during the 2-year follow-up. Thus, CSA and information on autoantibodies is insufficient for accurately identifying imminent autoantibody-positive RA.
Authors: Jing Shi; Rachel Knevel; Parawee Suwannalai; Michael P van der Linden; George M C Janssen; Peter A van Veelen; Nivine E W Levarht; Annette H M van der Helm-van Mil; Anthony Cerami; Tom W J Huizinga; Rene E M Toes; Leendert A Trouw Journal: Proc Natl Acad Sci U S A Date: 2011-10-10 Impact factor: 11.205
Authors: Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovský; Frederick Wolfe; Gillian Hawker Journal: Arthritis Rheum Date: 2010-09
Authors: Jing Shi; Lotte A van de Stadt; E W Nivine Levarht; Tom W J Huizinga; René E M Toes; Leendert A Trouw; Dirkjan van Schaardenburg Journal: Arthritis Rheum Date: 2013-04
Authors: Hanna W van Steenbergen; Jessica A B van Nies; Tom W J Huizinga; Johan L Bloem; Monique Reijnierse; Annette H M van der Helm-van Mil Journal: Ann Rheum Dis Date: 2014-04-09 Impact factor: 19.103
Authors: M P M van der Linden; M R Batstra; L E Bakker-Jonges; J Detert; H Bastian; H U Scherer; R E M Toes; G-R Burmester; M D Mjaavatten; T K Kvien; T W J Huizinga; A H M van der Helm-van Mil Journal: Arthritis Rheum Date: 2011-05
Authors: Solbritt Rantapää-Dahlqvist; Ben A W de Jong; Ewa Berglin; Göran Hallmans; Göran Wadell; Hans Stenlund; Ulf Sundin; Walther J van Venrooij Journal: Arthritis Rheum Date: 2003-10
Authors: Markus M J Nielen; Dirkjan van Schaardenburg; Henk W Reesink; Rob J van de Stadt; Irene E van der Horst-Bruinsma; Margret H M T de Koning; Moud R Habibuw; Jan P Vandenbroucke; Ben A C Dijkmans Journal: Arthritis Rheum Date: 2004-02
Authors: W H Bos; G J Wolbink; M Boers; G J Tijhuis; N de Vries; I E van der Horst-Bruinsma; P P Tak; R J van de Stadt; C J van der Laken; B A C Dijkmans; D van Schaardenburg Journal: Ann Rheum Dis Date: 2009-04-09 Impact factor: 19.103
Authors: Lotte Arwen van de Stadt; Birgit I Witte; Wouter H Bos; Dirkjan van Schaardenburg Journal: Ann Rheum Dis Date: 2012-11-23 Impact factor: 19.103
Authors: C Rakieh; J L Nam; L Hunt; E M A Hensor; S Das; L-A Bissell; E Villeneuve; D McGonagle; R Hodgson; A Grainger; R J Wakefield; P G Conaghan; P Emery Journal: Ann Rheum Dis Date: 2014-04-12 Impact factor: 19.103
Authors: Lise Hafkenscheid; Emma de Moel; Irene Smolik; Stacey Tanner; Xiaobo Meng; Bas C Jansen; Albert Bondt; Manfred Wuhrer; Tom W J Huizinga; Rene E M Toes; Hani El-Gabalawy; Hans U Scherer Journal: Arthritis Rheumatol Date: 2019-09-02 Impact factor: 10.995
Authors: Rochelle D Vergroesen; Linda M Slot; Barbera D C van Schaik; Marvyn T Koning; Theo Rispens; Antoine H C van Kampen; René E M Toes; Hans U Scherer Journal: Front Immunol Date: 2019-09-04 Impact factor: 7.561
Authors: Fenne Wouters; Marc P Maurits; Laurette van Boheemen; Marloes Verstappen; Kulveer Mankia; Xanthe M E Matthijssen; Annemarie L Dorjée; Paul Emery; Rachel Knevel; Dirkjan van Schaardenburg; René E M Toes; Annette H M van der Helm-van Mil Journal: Ann Rheum Dis Date: 2021-07-20 Impact factor: 19.103